Baxalta
About Baxalta
Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Ludwig Hantson
CFO: Robert Hombach
CSO (Scientific): John Orloff
JOBS:
Please click here for Baxalta job opportunitites.
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS: All Products
FOLLOW BAXALTA : Tweets by Baxalta
126 articles about Baxalta
-
FDA Gives Nod to Baxalta's Rare Bleeding Disorder Drug Vonvendi
12/9/2015
-
Baxalta Presents Additional Data On Newly-Approved ADYNOVATE And Plans For New Indications During 57th American Society of Hematology Annual Meeting
12/7/2015
-
Baxalta Receives CHMP Positive Opinion For Sanquin To Begin Production, Enhancing Global Supply Of Plasma-Based Therapies
12/3/2015
-
Baxalta Opens Up Shop at Kendall Square
12/3/2015
-
Baxalta To Showcase Innovation Leadership In Hematology And Oncology During 57th American Society of Hematology Annual Meeting
12/2/2015
-
Baxalta Announces U.S. Availability of ADYNOVATE, A New Treatment For Adult Patients With Hemophilia A With A Simple, Twice-Weekly Dosing Schedule
11/30/2015
-
Shire Rumored To Be Sweetening the Pot for Another Baxalta Bid
11/25/2015
-
Merrimack And Baxalta Announce Publication Of The ONIVYDE (irinotecan liposome injection) NAPOLI-1 Study In The Lancet
11/23/2015
-
Baxalta Receives Positive CHMP Opinion For Use Of ONCASPAR (Pegaspargase) In European Union As A Component Of Combination Therapy In Acute Lymphoblastic Leukaemia (ALL)
11/23/2015
-
Baxalta To Initiate A First-In-Human Clinical Trial Of BAX 826, An Investigational, Extended Half-Life FVIII Treatment Targeting Weekly Dosing For Hemophilia A
11/20/2015
-
Baxalta Declares Quarterly Dividend
11/18/2015
-
Baxalta To Advance Care For Hemophilia A Patients With FDA Approval Of ADYNOVATE, A Simple, Twice-Weekly Treatment To Reduce Bleeds
11/16/2015
-
Baxalta Gains EU Marketing Authorization To Provide OBIZUR To Adult Patients With Acquired Hemophilia A
11/13/2015
-
Coherus And Baxalta Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoints in Phase 3 Psoriasis Clinical Study (RaPsODY)
11/10/2015
-
Still Yearning for Baxalta, Shire Snaps Up Dyax in $5.9 Billion Deal
11/3/2015
-
Baxalta To Present At Credit Suisse Healthcare Conference
11/3/2015
-
Baxalta Announces Strong Sales And Earnings For Third Quarter Exceeding Guidance, Raises Second Half 2015 Outlook
10/29/2015
-
Shire CEO Believes Dry Eye Drug Will Boost Its Chances of Landing Baxalta
10/28/2015
-
Baxalta’s HYQVIA Honored With 2015 Chicago Innovation Award
10/28/2015
-
Merrimack And Baxalta Announce Enrollment Of First Patient In Phase 2 Study Of ONIVYDE (irinotecan Liposome Injection) In Previously Untreated Front-Line Metastatic Pancreatic Cancer
10/27/2015